Items where authors include "Horne, A."

Article

Horne, A., Brown, S., Butterworth, K. et al. (26 more authors) (2022) EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 17 (9). s267-s268. ISSN 1556-0864

Cronin, O. orcid.org/0000-0002-1365-9942, Forsyth, L., Goodman, K. et al. (39 more authors) (2019) Zoledronate in the prevention of Paget's (ZiPP) : protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone. BMJ Open, 9 (9). e030689.

Akande, V., Turner, C., Horner, P. et al. (3 more authors) (2010) Impact of Chlamydia trachomatis in the reproductive setting: British Fertility Society Guidelines for practice. Human Fertility, 13 (3). pp. 115-125. ISSN 1464-7273

Monograph

Jackson, T. orcid.org/0000-0002-1340-1888, Knowles, C. orcid.org/0000-0002-6969-7382, McLaughlin, S. orcid.org/0000-0001-5869-1869 et al. (4 more authors) (2023) Sustaining Practice Assets for Research, Knowledge, Learning and Engagement (SPARKLE) : Final Report and Recommendations. Report. University of Leeds

Conference or Workshop Item

Horne, A., Ali, A., Brown, S. et al. (28 more authors) (2022) 153 CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). In: 20th Annual British Thoracic Oncology Group Conference 2022, 27-28 Jan 2022, Virtual.

Proceedings Paper

Walls, G., Horne, A., Harrow, S. et al. (17 more authors) (2025) 3513: ATM inhibition with AZD1390 and conventional radiotherapy in non-small cell lung cancer: interim report from the CONCORDE phase Ib trial (NCT04550104). In: Radiotherapy and Oncology. ESTRO 2025, 02-06 May 2025, Vienna, Austria. , s1395-s1397.

Horne, A., Walls, G., Brown, S. et al. (17 more authors) (2025) An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRIs) in combination with conventional radiotherapy in NSCLC. In: Journal of Thoracic Oncology. European Lung Cancer Congress 2025, 26-29 Mar 2025, Paris, France. Elsevier BV , S150.

Walls, G., Horne, A., Franks, K. et al. (23 more authors) (2025) 255 An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRis) in combination with conventional radiotherapy in NSCLC. In: Lung Cancer. 23rd BTOG Annual Conference 2025, 03-05 Mar 2025, Belfast, Northern Ireland. Elsevier BV , p. 108364.

Horne, A., Brown, S., Gilbert, A. et al. (16 more authors) (2024) Modern era radical radiotherapy toxicity: a preliminary CONCORDE analysis of the calibration arm. In: Radiotherapy and Oncology. ESTRO 2024, 03-07 May 2024, Glasgow, UK. , S1652-S1655.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier BV , S296-S297.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier , S296-S297.